0|chunk|Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications
0	0	10 Clomiphene	Chemical	CHEBI_3752

1|chunk|The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract, tissues in which EBOV can persist. Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays. Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies. This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6). Visual problems have been noted in EBOV survivors, and viral RNA has been isolated from semen up to nine months post-infection. Since the clomiphene isomers accumulate in these affected tissues, clomiphene or one of its isomers warrants consideration as an anti-EBOV agent, for example, to potentially help ameliorate symptoms in EBOV survivors. 2 of 15 basis; these included the ZMapp cocktail of monoclonal antibodies [7, 8] , hyperimmune serum [9,10], and several low molecular weight anti-viral drugs [11] [12] [13] . Additional therapeutic antibodies [14] [15] [16] [17] have recently been described, and two novel low molecular weight viral RNA polymerase inhibitors are in development [18, 19] . A different approach has been to screen U.S. Food and Drug Administration (FDA)-approved drugs for anti-EBOV activity, with the goal of repurposing an approved drug, or combination of approved drugs, for use as a prophylactic and/or therapeutic in the advent of a future outbreak [20] [21] [22] [23] [24] . Clomiphene surfaced in two independent screens of FDA-approved drugs for anti-EBOV activity [20] [21] [22] ; it blocks EBOV entry and infection in tissue culture cells and provides up to 90% protection in the mouse model of EBOV disease [20, 21] . Clomiphene is a selective estrogen receptor modulator that is used to treat female infertility due to anovulation [25] [26] [27] . It was also proposed in 1991 as a drug to reverse impotence in men due to low testosterone levels [28] , and is currently used off-label for men with hypogonadism. We found, however, that clomiphene exerts its anti-EBOV activity in cell cultures irrespective of expression of the estrogen receptor alpha and/or beta subunits [20] . Instead, clomiphene likely exerts its anti-EBOV activity because it is a cationic amphiphilic drug [29] that accumulates in endolysosomes, the site of EBOV fusion and cytoplasmic entry [30] [31] [32] . Similar to other cationic amphiphilic drugs [29, 33] , clomiphene blocks a late step in the complex process by which the EBOV genome gains access to the host cell cytoplasm to initiate replication, most likely by blocking fusion between the EBOV and endolysosomal membranes [29] .
1	107	117 Clomiphene	Chemical	CHEBI_3752
1	128	132 Food	Chemical	CHEBI_33290
1	137	141 Drug	Chemical	CHEBI_23888
1	172	176 drug	Chemical	CHEBI_23888
1	285	295 clomiphene	Chemical	CHEBI_3752
1	323	330 mixture	Chemical	CHEBI_60004
1	567	577 clomiphene	Chemical	CHEBI_3752
1	708	718 Clomiphene	Chemical	CHEBI_3752
1	856	869 glycoproteins	Chemical	CHEBI_17089
1	1046	1049 RNA	Chemical	CHEBI_33697
1	1123	1133 clomiphene	Chemical	CHEBI_3752
1	1180	1190 clomiphene	Chemical	CHEBI_3752
1	1484	1489 drugs	Chemical	CHEBI_23888
1	1632	1635 RNA	Chemical	CHEBI_33697
1	1632	1657 RNA polymerase inhibitors	Chemical	CHEBI_37416
1	1647	1657 inhibitors	Chemical	CHEBI_35222
1	1733	1737 Food	Chemical	CHEBI_33290
1	1742	1746 Drug	Chemical	CHEBI_23888
1	1777	1782 drugs	Chemical	CHEBI_23888
1	1848	1852 drug	Chemical	CHEBI_23888
1	1881	1886 drugs	Chemical	CHEBI_23888
1	1995	2005 Clomiphene	Chemical	CHEBI_3752
1	2058	2063 drugs	Chemical	CHEBI_23888
1	2243	2253 Clomiphene	Chemical	CHEBI_3752
1	2269	2277 estrogen	Chemical	CHEBI_50114
1	2269	2296 estrogen receptor modulator	Chemical	CHEBI_50739
1	2278	2296 receptor modulator	Chemical	CHEBI_90710
1	2408	2412 drug	Chemical	CHEBI_23888
1	2452	2464 testosterone	Chemical	CHEBI_17347
1	2562	2572 clomiphene	Chemical	CHEBI_3752
1	2654	2662 estrogen	Chemical	CHEBI_50114
1	2672	2677 alpha	Chemical	CHEBI_30216
1	2685	2689 beta	Chemical	CHEBI_10545
1	2715	2725 clomiphene	Chemical	CHEBI_3752
1	2800	2804 drug	Chemical	CHEBI_23888
1	2946	2951 drugs	Chemical	CHEBI_23888
1	2963	2973 clomiphene	Chemical	CHEBI_3752
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_33290
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_23888
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_60004
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_17089
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_3752	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_23888
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_60004
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_17089
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_33290	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_60004
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_17089
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_17089
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_60004	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_17089	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_37416
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_37416	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_50114
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_35222	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_50114	CHEBI_50739
1	CHEBI-CHEBI	CHEBI_50114	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_50114	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_50114	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_50114	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_50739	CHEBI_90710
1	CHEBI-CHEBI	CHEBI_50739	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_50739	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_50739	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_90710	CHEBI_17347
1	CHEBI-CHEBI	CHEBI_90710	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_90710	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_17347	CHEBI_30216
1	CHEBI-CHEBI	CHEBI_17347	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_30216	CHEBI_10545

2|chunk|Clomiphene citrate, the clinically-administered drug and the formulation tested to date for anti-EBOV activity, is a mixture of two diastereoisomers:~60% trans-clomiphene (enclomiphene) and 40% cis-clomiphene (zuclomiphene). Whereas enclomiphene exhibits high anti-estrogenic properties, zuclomiphene does not [34] [35] [36] . The two isomers also differ in other pharmacokinetic properties. For examples, zuclomiphene has a longer half-life in serum [37, 38] and persists in most tissues for longer periods of time than enclomiphene [39] . It could, therefore, be proposed that zuclomiphene is the major contributor to adverse side effects seen in individuals given clomiphene citrate and, conversely, that enclomiphene would impart fewer side effects [39, 40] . Due to these features, as well as its ability to raise testosterone levels, enclomiphene is currently in clinical development as a treatment for secondary hypogonadism (low testosterone levels) [41] .
2	0	10 Clomiphene	Chemical	CHEBI_3752
2	0	18 Clomiphene citrate	Chemical	CHEBI_3753
2	11	18 citrate	Chemical	CHEBI_133748
2	48	52 drug	Chemical	CHEBI_23888
2	117	124 mixture	Chemical	CHEBI_60004
2	667	677 clomiphene	Chemical	CHEBI_3752
2	667	685 clomiphene citrate	Chemical	CHEBI_3753
2	678	685 citrate	Chemical	CHEBI_133748
2	819	831 testosterone	Chemical	CHEBI_17347
2	937	949 testosterone	Chemical	CHEBI_17347
2	CHEBI-CHEBI	CHEBI_3752	CHEBI_3753
2	CHEBI-CHEBI	CHEBI_3752	CHEBI_133748
2	CHEBI-CHEBI	CHEBI_3752	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_3752	CHEBI_60004
2	CHEBI-CHEBI	CHEBI_3752	CHEBI_17347
2	CHEBI-CHEBI	CHEBI_3753	CHEBI_133748
2	CHEBI-CHEBI	CHEBI_3753	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_3753	CHEBI_60004
2	CHEBI-CHEBI	CHEBI_3753	CHEBI_17347
2	CHEBI-CHEBI	CHEBI_133748	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_133748	CHEBI_60004
2	CHEBI-CHEBI	CHEBI_133748	CHEBI_17347
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_60004
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_17347
2	CHEBI-CHEBI	CHEBI_60004	CHEBI_17347

3|chunk|Because of the differing pharmacological features of enclomiphene and zuclomiphene and the ongoing clinical development of enclomiphene, we compared the effects of clomiphene and its isomers on EBOV entry and replication. We found that clomiphene, enclomiphene, zuclomiphene, and two of their primary metabolites (4-hydroxy-enclomiphene and 4-hydroxy-zuclomiphene) block EBOV entry and replication to similar levels. Compared to clomiphene, enclomiphene, and zuclomiphene displayed similar dose profiles for blocking EBOV entry and replication, as tested in two cell types and with the glycoproteins from two isolates of EBOV as well as from a Marburg virus.
3	164	174 clomiphene	Chemical	CHEBI_3752
3	236	246 clomiphene	Chemical	CHEBI_3752
3	293	312 primary metabolites	Chemical	CHEBI_25212
3	301	312 metabolites	Chemical	CHEBI_25212
3	429	439 clomiphene	Chemical	CHEBI_3752
3	586	599 glycoproteins	Chemical	CHEBI_17089
3	CHEBI-CHEBI	CHEBI_3752	CHEBI_25212
3	CHEBI-CHEBI	CHEBI_3752	CHEBI_17089
3	CHEBI-CHEBI	CHEBI_25212	CHEBI_17089

